Search results for "IBA"

showing 10 items of 1355 documents

The role of positive selection in hepatitis C virus

2008

Hepatitis C virus (HCV) is a major health problem worldwide, infecting an estimated 170 million people. In this study, we have employed a large data set of sequences (14,654 sequences from between 25 and 100 clone sequences per analyzed region and per patient) from 67 patients infected with HCV genotype 1 (23 subtype 1a and 44 subtype 1b). For all patients, a sample prior to combined therapy with alpha interferon plus ribavirin was available, whereas for some patients additional samples after 6 or 12 months of treatment were also available. Twenty-seven patients responded to treatment (12 subtype 1a and 15 subtype 1b) and forty patients did not respond to treatment (11 subtype 1a vs. 29 sub…

Microbiology (medical)Hepatitis C virusAlpha interferonHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeMicrobiologyCohort Studieschemistry.chemical_compoundViral Envelope ProteinsSequence Analysis ProteinInterferonDrug Resistance ViralRibavirinGeneticsmedicineHumansAmino Acid SequenceSelection GeneticNS5AMolecular BiologyEcology Evolution Behavior and SystematicsChi-Square DistributionRibavirinInterferon-alphaHepatitis Cmedicine.diseaseComplementarity Determining RegionsHepatitis CVirologyHypervariable regionInfectious DiseaseschemistryImmunologyViral hepatitismedicine.drugInfection, Genetics and Evolution
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct

Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

2001

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/ day orally in 2 divided doses, or chloramphenicol, 50 mg/ kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P = .047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.

Microbiology (medical)Malemedicine.medical_specialtyBoutonneuse FeverGastroenterologylaw.inventionRandomized controlled trialOral administrationlawClarithromycinInternal medicineClarithromycinmedicineHumansChildAntibacterial agentclarithromycin Mediterranean spotted feverbusiness.industryChloramphenicolmedicine.diseaseSpotted feverSurgeryAnti-Bacterial AgentsBoutonneuse feverInfectious DiseasesRickettsiosisChloramphenicolChild PreschoolFemalebusinessmedicine.drug
researchProduct

MRSA infection in the neonatal intensive care unit

2013

Methicillin-resistant Staphylococcus aureus (MRSA) is well known as one of the most frequent etiological agents of healthcare-associated infections. The epidemiology of MRSA is evolving with emergence of community-associated MRSA, the clonal spread of some successful clones, their spillover into healthcare settings and acquisition of antibacterial drug resistances. Neonatal intensive care unit (NICU) patients are at an especially high risk of acquiring colonization and infection by MRSA. Epidemiology of MRSA in NICU can be very complex because outbreaks can overlap endemic circulation and make it difficult to trace transmission routes. Moreover, increasing prevalence of community-associated…

Microbiology (medical)Methicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyNeonatal intensive care unitMRSA infectionSettore MED/42 - Igiene Generale E ApplicataMicrobiologySettore MED/38 - Pediatria Generale E SpecialisticaVirologyIntensive Care Units NeonatalEpidemiologymedicinePrevalenceInfection controlHumansIntensive care medicineAntibacterial drugDeveloping CountriesInfection Controlbusiness.industryTransmission (medicine)Developed CountriesAustraliaInfant NewbornMRSA CA-MRSA HA-MRSA NICU epidemiology prevention controlOutbreakbiochemical phenomena metabolism and nutritionStaphylococcal Infectionsbacterial infections and mycosesUnited StatesAnti-Bacterial AgentsEuropeInfectious DiseasesEpidemiological MonitoringEpidemiological Monitoringbusiness
researchProduct

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

2005

To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC(90) values of 0.125 mg/L. Linezolid was active against all isolates with MIC(50) and MIC(90) values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or interm…

Microbiology (medical)MoxifloxacinMicrobial Sensitivity TestsBiologyMicrobiologychemistry.chemical_compoundMoxifloxacinClarithromycinClarithromycinAcetamidesDrug Resistance Bacterialpolycyclic compoundsmedicineHumansheterocyclic compoundsPharmacology (medical)OxazolidinonesEthambutolAntibacterial agentPharmacologyMycobacterium kansasiiAza CompoundsIsoniazidLinezolidbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationAnti-Bacterial AgentsInfectious DiseaseschemistryMycobacterium kansasiiLinezolidQuinolinesbacteriaRifampicinFluoroquinolonesmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies …

1996

Important species differences have been reported concerning the induction properties of rifampicin towards enzymes of the P-450 superfamily. Mice, rabbits and humans are far more responsive than rats and guinea pigs. In the present study a strong induction of cytochrome P-450 3A-dependent enzyme activities was observed in female rat liver microsomes after high dose treatment (> or = 250 mg/kg/day for 9 days) with rifampicin, resulting in an up to 30-fold enhanced hydroxylation rate of testosterone in the 2 beta-, 6 beta- and 15 beta-position in vitro. Other cytochrome P-450 isozyme-selective reactions were not, or only marginally, affected. A steep increase in cytochrome P-450 3A activity o…

Microbiology (medical)RifabutinCYP3AGlucuronidation10050 Institute of Pharmacology and Toxicology610 Medicine & healthPharmacologyBiology2726 Microbiology (medical)Cytochrome P-450 Enzyme Systempolycyclic compoundsmedicineAnimals2736 Pharmacology (medical)TestosteronePharmacology (medical)GlucuronosyltransferaseRats WistarEnzyme inducerAntibiotics AntitubercularAntibacterial agentPharmacologyDose-Response Relationship DrugCytochrome P4502725 Infectious Diseasesbacterial infections and mycosesRatsInfectious Diseases3004 PharmacologyLiverRifabutinMicrosomebiology.protein570 Life sciences; biologyFemaleRifampinRifampicinmedicine.drug
researchProduct

Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy.

2002

ABSTRACT From 1992 to 1997, only six sporadic isolates of Salmonella enterica serotype Enteritidis from patients with cases of gastroenteritis in southern Italy exhibited resistance to broad-spectrum cephalosporins. Five isolates produced SHV-12, and one isolate encoded a class C β-lactamase. The bla SHV-12 gene was located in at least two different self-transferable plasmids, one of which also carried a novel class 1 integron.

Microbiology (medical)Serotypemedicine.drug_classEpidemiologySalmonella enteritidisCephalosporinIntegronbeta-LactamasesMicrobiologyPlasmidDrug Resistance Multiple BacterialGenotypemedicineHumansamoxicillin plus clavulanic acid; ampicillin; antibiotic agent; aztreonam; beta lactamase; cefotaxime; cefoxitin; ceftazidime; cephalosporin derivative; chloramphenicol; kanamycin; plasmid DNA; streptomycin; sulfonamide; tobramycin antibiotic resistance; article; bacterial infection; bacterium isolate; DNA probe; gastroenteritis; gastrointestinal infection; Italy; nonhuman; nucleotide sequence; phenotype; plasmid; priority journal; Salmonella; Salmonella enterica Base Sequence; beta-Lactamases; Cephalosporin Resistance; Cross Infection; Drug Resistance Multiple Bacterial; Gastroenteritis; Genes Bacterial; Humans; Italy; Plasmids; Salmonella enteritidis; Salmonella Infections Bacteria (microorganisms); Negibacteria; Salmonella; Salmonella entericaCephalosporin ResistanceCross InfectionbiologyBase SequenceCephalosporin Resistancebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationVirologyGastroenteritisItalySalmonella enteritidisSalmonella entericaGenes BacterialSalmonella Infectionsbiology.proteinPlasmidsJournal of clinical microbiology
researchProduct

Daptomycin non-susceptible, vancomycin intermediate methicillin-resistant Staphylococcus aureus ST398 from a chronic leg ulcer, Italy

2010

To the Editor,Human infections caused by methicillin-resistant Staphylococcus aureus (MRSA) sequence type 398 (ST398) have been emerging in recent y in Europe [1–3]. Most studies have shown a stron...

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaMicrococcaceaeGeneral Immunology and Microbiologybiologymedicine.drug_classbusiness.industryAntibioticsGeneral Medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.disease_causebiology.organism_classificationMethicillin-resistant Staphylococcus aureusMicrobiologyInfectious DiseasesStaphylococcus aureusmedicineMRSA daptomycin drug resistanceVancomycinDaptomycinbusinessmedicine.drugAntibacterial agentStaphylococcal Skin InfectionsScandinavian Journal of Infectious Diseases
researchProduct

Simultaneous identification of campylobacters and prediction of quinolone resistance by comparative sequence analysis.

1997

Comparative sequence analysis of a 30-bp segment in the quinolone resistance-determining region of campylobacters not only allows for the detection of base changes associated with resistance but also is a powerful tool for species identification based on silent mutations.

Microbiology (medical)Silent mutationDNA Bacterialmedicine.drug_classSequence analysisSequence alignmentBiologymedicine.disease_causeDNA gyrasePolymerase Chain Reactionlaw.inventionAnti-Infective AgentsSpecies SpecificitylawmedicinePolymerase chain reactionAntibacterial agentGeneticsMutation4-QuinolonesSequence Homology Amino AcidCampylobacterDrug Resistance MicrobialSequence Analysis DNAQuinoloneDNA Topoisomerases Type IIDNA GyraseSequence AlignmentResearch Article
researchProduct

Comparison of Two Schizophyllum commune Strains in Production of Acetylcholinesterase Inhibitors and Antioxidants from Submerged Cultivation

2021

In recent years, fungi have been recognized as producers of acetylcholinesterase (AChE) inhibitors, agents important for the prevention of Alzheimer’s disease (AD). This study aimed to examine the AChE inhibitory, the antioxidative and antibacterial activity of two different Schizophyllum commune strains that originated from Serbia (SRB) and Italy (IT). Submerged cultivation of grown mycelia (M) and fermentation broth (F) of ethanol (EtOH) and polysaccharide (PSH) extracts lasted for 7, 14, 21 and 28 days. For AChE activity Ellman method was performed, while for antioxidative activity, sevendifferent assays were conducted: DPPH, ABTS, FRAP, SOA, OH, NO together with total phenolic content. …

Microbiology (medical)Submerged cultivationAntioxidantDPPH<i>Schizophyllum commune</i>medicine.medical_treatmentAcetylcholinesterase inhibitionPlant ScienceSchizophyllum commune01 natural sciencesArticle03 medical and health scienceschemistry.chemical_compoundmedicineFood sciencelcsh:QH301-705.5Ecology Evolution Behavior and SystematicsMycelium030304 developmental biology0303 health sciencesABTSbiology010405 organic chemistrySettore BIO/02 - Botanica SistematicaSchizophyllum communebiology.organism_classificationAntimicrobialAcetylcholinesterase0104 chemical scienceslcsh:Biology (General)chemistrySettore BIO/03 - Botanica Ambientale E ApplicataAntioxidantAntibacterial activityJournal of Fungi
researchProduct